2,037 Shares in CRISPR Therapeutics AG (NASDAQ:CRSP) Acquired by MCF Advisors LLC

MCF Advisors LLC purchased a new stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 2,037 shares of the company’s stock, valued at approximately $80,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. American Century Companies Inc. increased its stake in shares of CRISPR Therapeutics by 4.0% in the second quarter. American Century Companies Inc. now owns 18,411 shares of the company’s stock valued at $994,000 after buying an additional 703 shares during the period. Dimensional Fund Advisors LP increased its position in CRISPR Therapeutics by 2.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 950,149 shares of the company’s stock valued at $51,326,000 after purchasing an additional 19,094 shares during the period. Mercer Global Advisors Inc. ADV raised its holdings in CRISPR Therapeutics by 4.3% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 10,787 shares of the company’s stock worth $583,000 after purchasing an additional 447 shares during the last quarter. Vanguard Personalized Indexing Management LLC lifted its position in shares of CRISPR Therapeutics by 13.2% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 4,167 shares of the company’s stock worth $225,000 after purchasing an additional 486 shares during the period. Finally, Hsbc Holdings PLC bought a new stake in shares of CRISPR Therapeutics in the 2nd quarter valued at $1,449,000. 69.20% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

CRSP has been the topic of several recent analyst reports. StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a report on Monday, December 30th. Needham & Company LLC restated a “buy” rating and set a $84.00 target price on shares of CRISPR Therapeutics in a research report on Tuesday, January 14th. Barclays cut their price target on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating on the stock in a report on Wednesday, November 6th. Chardan Capital reiterated a “buy” rating and set a $94.00 target price on shares of CRISPR Therapeutics in a research report on Tuesday, December 10th. Finally, Bank of America reduced their price target on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $78.38.

CRISPR Therapeutics Trading Up 6.5 %

Shares of NASDAQ:CRSP opened at $44.20 on Thursday. The stock has a market cap of $3.77 billion, a PE ratio of -15.62 and a beta of 1.68. The stock’s fifty day simple moving average is $44.43 and its two-hundred day simple moving average is $47.88. CRISPR Therapeutics AG has a 1-year low of $36.52 and a 1-year high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.42) by $0.41. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. The company had revenue of $0.60 million for the quarter, compared to analyst estimates of $6.65 million. During the same period last year, the firm earned ($1.41) earnings per share. On average, sell-side analysts forecast that CRISPR Therapeutics AG will post -5.13 earnings per share for the current fiscal year.

Insider Transactions at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 15,000 shares of the business’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $55.10, for a total value of $826,500.00. Following the transaction, the chief executive officer now owns 181,540 shares of the company’s stock, valued at approximately $10,002,854. The trade was a 7.63 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 4.10% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.